Within‐individual studies
Study	Interventions	Summary Outcomes	Comment
Munavalli 2013	One side: Injectable filler using autologous fibroblasts injected into the dermis Other side: vehicle control (dye‐free, protein‐free cell culture medium) injected into the dermis	Improvement of acne scars: More than twice as many participants rated the injectable filler treated area with a 2‐point or greater improvement than the area receiving vehicle control (43% vs 18%). Evaluators rated 59% of the injectable filler–treated sides with a 1‐point or greater improvement on the evaluator scale compared with 42% of the sides receiving vehicle control. Side effects: No participants experienced serious adverse events, discontinued treatment, or withdrew from the study as a result of a treatment‐emergent adverse event. The most common adverse events were treatment area erythema (occurring in 11.1% of participants) and swelling (occurring in 10.1% of participants).	Munavalli 2013 did not report the secondary outcomes ‘Participant satisfaction’, ‘Quality of life’, ‘Participant‐reported adverse events’ and ‘Post‐procedure down time’.